Policy & Regulation
Flerie portfolio company Bonsai Biotherapeutics secures clinical trial approval for TOL2 in myasthenia gravis
26 June 2026 - Life science investor Flerie AB (STO:FLERIE) announced on Friday that its portfolio company Bonsai Biotherapeutics has received full approval of its clinical trial application for TOL2 ...
MaaT Pharma to seek review after CHMP negative opinion on MaaT013 application
26 June 2026 - Clinical-stage biotechnology company MaaT Pharma (Euronext Paris:MAAT) said on Friday that it will request a re-examination of the European Medicines Agency's Committee for Medicin...
Racura Oncology doses first patient in Phase 1 lung cancer trial
26 June 2026 - Australian-based clinical-stage biopharmaceutical company Racura Oncology Limited (ASX:RAC) announced on Thursday that the first patient has been dosed with RC220 in HARNESS-1, a Phase ...
NeuroSense reports Phase 2 proof-of-concept study results for PrimeC in Alzheimer's Disease
26 June 2026 - Late-clinical stage biotechnology company NeuroSense Therapeutics Ltd (NASDAQ:NRSN) on Thursday reported positive biomarker findings from its Phase 2 randomised, double-blind, placebo-c...
LyGenesis granted funding for research project to induce immune tolerance to pancreatic islet transplantation
26 June 2026 - LyGenesis, Inc., a US-based, clinical-stage biotechnology company developing cell therapies for organ regeneration, announced on Thursday that it has received a research award from Brea...
Servier enrols first US patient in Phase Ib/II paediatric epilepsy study
26 June 2026 - French pharmaceutical company Servier said on Thursday that the first patient has been enrolled in the US in a Phase Ib/II first-in-human study to evaluate the safety, tolerability, pha...